Welcome New Members January 2024

Posted by ISPE Boston
On February 5, 2024

We would like to introduce the Members who joined ISPE in January 2024, welcome them to the Chapter, and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]

Cozy Evening at the Winter Social!

Posted by Kathryn Tarantino
On January 26, 2024

On Thursday, January 25th, the Social and Emerging Leaders Committees hosted the annual Winter Social at Night Shift Brewery in Boston. Over 100+ professionals in the Boston area came together while enjoying a wide selection of craft beers and delicious appetizers. Two lucky raffle winners walked away with more than new connections! Caren Jenkins won […]

LAST CHANCE – Call for Presentations for 2024 Product Show!

Posted by ISPE Boston
On January 23, 2024

For Life Science professionals at all levels working directly for drug manufacturers, their suppliers, and the educational institutions that are training the next generation of industry professionals, the Product Show offers an opportunity to share best practices and learn from experts about the most significant, practical, and current topics in the industry. This notice is […]

Vertex Sickle Cell Therapy Gets Second FDA Approval

Posted by ISPE Boston
On January 18, 2024

The FDA has approved the Vertex Pharmaceuticals CRISPR/Cas9 gene-edited cell therapy called Casgevy for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older. “On the heels of the historic FDA approval of Casgevy for sickle cell disease [SCD], it is exciting to now secure approval for TDT well ahead of the […]

Vertex CRISPR/Cas9 Gene-Edited Cell Therapy Process Explained

Posted by ISPE Boston
On January 18, 2024

Vertex Pharmaceuticals’ Casgevy is a one-time therapy used to treat people with sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The administration of Casgevy requires experience in stem cell transplantation thus Vertex is engaging with experienced hospitals to establish a network of authorized treatment centers throughout the U.S. to offer Casgevy to patients. Casgevy is made specifically for […]

Novo Nordisk Inks Obesity-Related R&D Deals with Local Biotechs

Posted by ISPE Boston
On January 11, 2024

As the first two programs signed under its collaboration with Flagship Pioneering, Novo Nordisk has entered into separate research collaborations with Omega Therapeutics and Cellarity. The companies, both founded by Flagship Pioneering in 2017, are based in Cambridge and Somerville, respectively. The Omega collaboration will leverage its proprietary platform technology to develop a potential new […]

Voyager Gets $100 Million from Novartis to Advance Novel Gene Therapies

Posted by ISPE Boston
On January 11, 2024

Chapter Member Anniversaries: January 2024

Posted by ISPE Boston
On January 5, 2024

Please congratulate the following members celebrating milestone anniversaries in January 2024. Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Michael L. Anderson, FST Technical Services LLC Daniel E. Baxter, Vertex Pharmaceuticals Incorporated Robert G. Beane, Jr., Barry-Wehmiller Design Group Dr. Anthony C. Bevilacqua, Ph.D., Mettler-Toledo Thornton Inc […]

Welcome New Members December 2023!

Posted by ISPE Boston
On January 5, 2024

We would like to introduce the Members who joined ISPE in December 2023, welcome them to the Chapter and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]

BMS Acquires Karuna in $14 Billion Deal

Posted by ISPE Boston
On January 4, 2024

Bristol Myers Squibb has agreed to acquire Boston-based biopharma Karuna Therapeutics for $330 per share in a transaction valued at $14 billion. Karuna is focused on therapies for psychiatric and neurological conditions with a lead asset called KarXT, an antipsychotic with a novel mechanism of action and differentiated efficacy and safety. Karuna’s NDA for KarXT […]

Page 14 of 118«‹12 131415 16 ›»